SELLAS CEO Claims GPS Has 'Very Good Chance' to Beat AML
CEO Angelos Stergiou has stated GPS has a "very good chance" to beat prior survival outcomes, with SELLAS's $2.42 billion valuation staked almost entirely on the Phase 3 AML trial outcome. A 27.4% sho
SELLAS CEO Claims GPS Data Has 'Very Good Chance' to Win
NEW YORK, October 21 —
SELLAS Life Sciences Group, Inc. (SLS) sits just two deaths from the Phase 3 AML final-analysis trigger, and CEO Angelos Stergiou has stated publicly that GPS data has a "very good chance" to beat prior survival outcomes. The same stock carries 27.4% short interest, a direct expression that a large fraction of the market expects the opposite.
- Final-analysis trigger: 80 deaths; 78 events confirmed as of May 11, two away from the readout.
- Shares trade at $11.98, $2.42B market cap; analyst consensus at $32.50, implying 171% upside.
- $140M cash, zero debt, ~$28M annual cash outflow; no product revenue, 13 employees.
Two Events From the Verdict
GPS is a peptide immunotherapy targeting the Wilms tumor 1 antigen, evaluated in hematologic malignancies including AML in a Merck collaboration that pairs it with the PD-1 blocker pembrolizumab. The company, 13 employees with no product revenue, has staked its $2.42 billion valuation almost entirely on this trial. With 78 deaths confirmed as of May 11 against the 80-event trigger, the final analysis window has effectively opened. Stergiou's public confidence claim, made on record before that trigger fires, is unusual: clinical-stage CEOs rarely attach probability language to binary readouts with this specificity, and this one did it with the outcome clock nearly expired.
The Short Case vs. the CEO's Signal
A 27.4% short interest positions SLS among the most contested stocks in biotech; short sellers are betting survival curves disappoint when data arrives. Stergiou's public optimism lands in that context as either genuine scientific conviction or pre-readout sentiment management, and the two readings carry opposite implications for anyone holding equity. Jim Cramer's "two thumbs up" endorsement and a 90% surge in Stocktwits message volume drove the stock 5.11% higher on October 19; track SELLAS Life Sciences Group's latest numbers. Insider ownership at just 0.9% means management's financial stake in being right is limited.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| SLS | $2.4B | n/a | +514.4% |
| GLSI | $238M | n/a | +79.2% |
| IMMP | $24M | n/a | -92.1% |
| VTVT | $110M | n/a | +33.9% |
| IBRX | $9.3B | n/a | +271.6% |
| CAPR | $384M | n/a | +3.8% |
What the Hazard Ratio Decides
SLS009 (tambiciclib), a selective CDK9 inhibitor, drew bullish commentary on new pancreatic cancer data, adding a secondary catalyst that exists independently of the AML binary. SELLAS holds $140 million in cash with zero debt against roughly $28 million in annual cash outflow, yielding several years of runway regardless of GPS. The number that settles the debate is the hazard ratio from the final analysis: analyst consensus at $32.50 assumes approval while the short cohort has priced failure. With the 80th event potentially imminent, the verdict may arrive before the next quarterly report. See the full DCF model and price target →
Current fundamentals, valuation and filing history for SELLAS Life Sciences Group, Inc. (SLS) are tracked on its Basis Report page.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When will SELLAS GPS AML trial results come out?
With 78 deaths confirmed as of May 11 against the 80-event trigger for final analysis, the readout is imminent. The verdict may arrive before the next quarterly report.
Why is SELLAS stock heavily shorted?
SELLAS carries 27.4% short interest, positioning it among the most contested stocks in biotech. Short sellers are betting survival curves will disappoint when GPS trial data arrives, contradicting CEO Angelos Stergiou's public optimism about a "very good chance" to beat prior outcomes.
What is SELLAS's stock price and valuation?
SELLAS trades at $11.98 with a $2.42 billion market cap. Analyst consensus sits at $32.50, implying 171% upside from current levels.
What is GPS and how is it being tested?
GPS is a peptide immunotherapy targeting Wilms tumor 1 antigen, evaluated in hematologic malignancies including AML. It is being tested in a Merck collaboration that pairs GPS with pembrolizumab, a PD-1 blocker.
What is SELLAS's financial runway?
SELLAS holds $140 million in cash with zero debt against roughly $28 million in annual cash outflow, providing several years of runway regardless of the GPS trial outcome.
SELLAS Life Sciences CEO Angelos Stergiou stated publicly that GPS AML clinical data has a 'very good chance' to beat earlier survival outcomes — a rare on-record confidence claim just before the final-analysis trigger — while Jim Cramer added a 'two thumbs up' endorsement. The same stock carries 27.4% short interest, meaning a large fraction of the market has placed exactly the opposite bet.